Technion - Israel Institute of Technology

The Israeli institute will share its expertise on translating research into commercially viable applications with the goal of advancing personalized medicine.

Researchers are developing a nanopore sensing device that relies on restriction enzymes to target specific clinically relevant variants in pathogens. 

Technion's Reut Shalgi is building up her lab to study how chaperones affect protein synthesis and protein folding.

The majority of the funding will be used to establish a cancer metabolomics research center on Technion's campus. 

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.